Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many pharmaceutical companies have promised to build.

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

Since becoming Vertex's top scientist in 2015, Altshuler has shaped the company’s efforts to expand beyond cystic fibrosis.

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...

The president said he would first install a “small tariff” on pharmaceutical goods before ratcheting up the rate over the ...